Haematology Trials

  • Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome

    View Trial
  • 13/02/2025

    A RANDOMIZED (1:1) DOUBLE-BLIND MULTI-CENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

    View Trial
  • 31/12/2019

    CC-5013-MDS-010

    A prospective non-interventional post-authorization safety study (PASS) designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q)

    View Trial
  • 31/12/2015

    The UK TARGET-CML study

    Real world UK use of Tyrosine Kinase Inhibitors (TKIs): A Retrospective description of manaGement pathways clinical responses and compliance with 2013 European LeukemiaNeT (ELN) recommendations for Chronic Myeloid Leukemia (CML) – the UK TARGETCML

    View Trial
  • 28/02/2019

    REAL

    REd cell transfusion in Acute myeloid Leukaemia

    View Trial
  • 31/07/2021

    OOHSCT

    Ocular and Oral Complications of Haemopoietic Stem Cell Transplant

    View Trial
  • 01/10/2016

    CHEMO-T

    Cyclophosphamide doxorubicin vincristine and prednisolone (CHOP) versus gemcitabine cisplatin and methyl prednisolone (GEMP) Of T-cell Lymphoma a multicentre randomised phase II study

    View Trial
  • 31/12/2011

    Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma

    View Trial
  • 01/07/2020

    MATCHPOINT

    Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study

    View Trial
  • 31/05/2020

    Dissecting mechanisms of regulation of gene expression in human leukaemia.

    View Trial